Publication:
Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.

dc.contributor.authorBernardo, Miquel
dc.contributor.authorRico-Villademoros, Fernando
dc.contributor.authorGarcía-Rizo, Clemente
dc.contributor.authorRojo, Rosa
dc.contributor.authorGómez-Huelgas, Ricardo
dc.date.accessioned2024-02-19T15:26:49Z
dc.date.available2024-02-19T15:26:49Z
dc.date.issued2021-04-07
dc.description.abstractTo assess the risk of occurrence and potential determinants of metabolic disorders in adult patients treated with second-generation antipsychotics (SGAs) under real-world practice conditions. MEDLINE, EMBASE, and PsycInfo were searched in July 2019 from database inception. We included population-based, longitudinal, comparative studies that report the results of the outcomes of interest for adult participants, including diabetes, ketoacidosis, hyperosmolar hyperglycemic state, weight gain/obesity, dyslipidemia, hypertension, and metabolic syndrome. Two reviewers independently extracted data on the study design, study quality, and study outcomes. We included 40 studies. Most studies showed that clozapine and olanzapine were associated with an increased likelihood of developing diabetes, while the results for risperidone and quetiapine were mixed. Although less well studied, ziprasidone and aripiprazole appeared to not be associated with the occurrence of diabetes. Information on antipsychotic-induced weight gain/obesity is extremely scarce. Regarding dyslipidemia, aripiprazole was not associated with an increased likelihood of developing dyslipidemia, clozapine was associated with an increased likelihood of developing dyslipidemia, and risperidone, olanzapine, quetiapine, and ziprasidone showed mixed results. Two studies suggested an association between ziprasidone and the occurrence of hypertension. Several studies found that the occurrence of a metabolic disorder acted as a risk factor for the development of other metabolic disorders. We did not find information on brexpiprazole, cariprazine, or lurasidone, and data on any long-acting SGA were lacking. Although there are relevant differences among SGAs concerning the risk of metabolic disorders, it appears that none of the SGAs included in our review are fully devoid of these disturbances.
dc.format.number5es_ES
dc.format.page2491-2512es_ES
dc.format.volume38es_ES
dc.identifier.doi10.1007/s12325-021-01689-8
dc.identifier.e-issn1865-8652es_ES
dc.identifier.journalAdvances in therapyes_ES
dc.identifier.otherhttp://hdl.handle.net/10668/17537
dc.identifier.pubmedID33826090es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18307
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectAntipsychotic
dc.subjectDiabetes
dc.subjectDyslipidemia
dc.subjectHyperosmolar hyperglycemic state
dc.subjectHypertension
dc.subjectKetoacidosis
dc.subjectMetabolic syndrome
dc.subjectObesity
dc.subjectWeight gain
dc.subject.meshAdult
dc.subject.meshAntipsychotic Agents
dc.subject.meshClozapine
dc.subject.meshHumans
dc.subject.meshOlanzapine
dc.subject.meshQuetiapine Fumarate
dc.subject.meshRisperidone
dc.titleReal-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files